| Literature DB >> 31058109 |
Yu Qiu1,2, Ruihua Shi1,2.
Abstract
Background and Purposes: Endoscopic resection has been worldwide recognized as a treatment strategy for early esophageal lesions. The occurrence of esophageal stricture after endoscopic resection will reduce the quality of life of patients. This study will evaluate the efficacy and safety of steroids in the prevention of esophageal stricture after endoscopic resection and the influence of different steroid administration methods.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31058109 PMCID: PMC6463667 DOI: 10.1155/2019/5380815
Source DB: PubMed Journal: Can J Gastroenterol Hepatol ISSN: 2291-2789
Clinical outcomes of oral steroid method of preventing esophageal stricture after endoscopic resection.
| Author, year | Design | Setting | Sample size | Follow-up | Stricture rate | Mean or median number of EBD | Adverse event |
|---|---|---|---|---|---|---|---|
| Lizuka, 2018 [ | Retrospective cohort study | ESD | 11/11 | Gastroscopy: 1, 4, 8, 12, 16, and 20 weeks after ESD | 36.4%VS 82% | 6.2 VS 19.4 | 8 VS 3 |
| Zhou, 2017 [ | Retrospective cohort study | ESD | 13/10 | Gastroscopy: 1, 3, 6, and 12 months after ESD | 23.1%VS 80% | 0.69 VS 13.5 | None |
| Jean-Philippe,2017 [ | Single-center retrospective study | EMR | 29/0 | Gastroscopy: 2, 6, 12, and 24 months after EMR | 13% | 2 | None |
| Mikinori, 2015[ | Retrospective cohort study | ESD | 17/16 | Gastroscopy: 8 weeks after ESD | 17. 6%VS | 4.6 VS 8.1 | None |
| Hiroki, 2013 [ | Retrospective cohort study | ESD | 10/13 | Gastroscopy: 7 days, 2-, 3-, and 4-week interval until 9thweek after negative endoscopy | Both 100% | 13.8 VS 33.5 | None |
| Naoyuki, 2011 [ | Case report | ESD | 1/0 | Gastroscopy: 1, 3, and 6 months after ESD | 0% | 0 | None |
| Hajime, 2011 [ | Retrospective study | ESD | 4/3 | Gastroscopy: 3, 6, and 12 months after ESD and then annually thereafter | Both 100% | 3.25 VS 32.67 | None |
| Naoyuki, 2011 [ | Retrospective study | ESD | 19/22 | Gastroscopy: 1, 3, 6, and 12 months after ESD and then annually thereafter | 5.3%VS31.8% | 1.7 VS 15.6 | None |
SEC, superficial esophageal cancer; ESCC, esophageal squamous cell carcinomas.
Clinical outcomes of local steroid injection of preventing esophageal stricture after endoscopic resection.
| Author, year | Design | Setting | Sample size | Follow-up | Stricture rate | Mean or median number of EBD | Adverse event |
|---|---|---|---|---|---|---|---|
| Tsujii, 2017 [ | Retrospective study | ESD>75% | 28/10 | Gastroscopy: a few months after ESD | 43% VS 90% (P=0.012) | 8 VS 5 | 5 VS 1 |
| Yasuaki, 2017 [ | Retrospective study | ESD>2/3but | 37/37 | Gastroscopy: every 4 weeks after ESD or receiving complaints of dysphagia | 18.9% VS 45.9% | 0.6±1.5 VS | None |
| Furuhashi, 2017 [ | Historical control study | ESD≥30mm diameter or ≥3/4 | 43/25 | Not mentioned | Multivariate analysis: OR:0.041,95%CI:0.007 to 0.24, p<0.001 | 2.3 VS 10.9 | None |
| Xu, 2016 [ | Randomized controlled trial | ESD≥1/2 | 17/23 | Not mentioned | 29.4% VS 69.6% | 0.5 VS 1.3 | 1 VS 0 |
| Yoshiki, 2016 [ | Retrospective study | ESD>1/2 | 30/15 | Not mentioned | 40% VS 60% | Not significantly different | 6 VS 0 |
| Yasuaki, 2016 [ | Retrospective study | >2/3but<3/4 | 28/28 | Gastroscopy: 4 and 8 weeks after the treatment. | 10.7% VS 35.7% | Not mentioned | Not mentioned |
| Takahashi, 2015 [ | Prospective study | ESD>75% | 16/16 | Not mentioned | 62.5% VS 87.5% | 6.1 VS 12.5 | 1.0% VS 0. 5% |
| Lee, 2013 [ | Case report | ESD 100% | 1/0 | Gastroscopy: 2 and 4 weeks and 4 months after ESD. Total follow-up time lasts for 6 months. | 0% | 0 | None |
| Hanaoka, 2012 [ | Prospective study | ESD>75% but<100% | 30/29 | Gastroscopy: whenever patients reported dysphagia and 2 months after ESD in patients without dysphagia. | 10% VS 66% | 0 VS 2 | 2 VS 0 |
| Satoru,2011 [ | Retrospective | ESD | 21/20 | Gastroscopy: assess for stenosis at 1 | 19% VS 75% | 1.7 VS 6.6 | None |
SENs, superficial esophageal neoplasms; LSI, local steroid injection; DSP, dexamethasone sodium phosphate; TA, triamcinolone acetonide; TTI, topical triamcinolone injection; ESCC, esophageal squamous cell carcinoma.